Oxford Immunotec Global PLC (OXFD) Position Lowered by Bank of America Corp DE

Bank of America Corp DE lessened its holdings in shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) by 27.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,700 shares of the company’s stock after selling 14,490 shares during the quarter. Bank of America Corp DE’s holdings in Oxford Immunotec Global were worth $482,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also made changes to their positions in OXFD. Polar Capital LLP grew its stake in Oxford Immunotec Global by 2.3% in the fourth quarter. Polar Capital LLP now owns 2,557,973 shares of the company’s stock worth $32,691,000 after purchasing an additional 58,351 shares during the period. BlackRock Inc. grew its stake in Oxford Immunotec Global by 2.4% in the third quarter. BlackRock Inc. now owns 1,310,098 shares of the company’s stock worth $21,264,000 after purchasing an additional 30,774 shares during the period. Bellevue Group AG grew its stake in Oxford Immunotec Global by 38.2% in the fourth quarter. Bellevue Group AG now owns 306,606 shares of the company’s stock worth $3,918,000 after purchasing an additional 84,769 shares during the period. Northern Trust Corp grew its stake in Oxford Immunotec Global by 0.7% in the fourth quarter. Northern Trust Corp now owns 290,723 shares of the company’s stock worth $3,715,000 after purchasing an additional 2,113 shares during the period. Finally, Essex Investment Management Co. LLC grew its stake in Oxford Immunotec Global by 2.0% in the fourth quarter. Essex Investment Management Co. LLC now owns 174,499 shares of the company’s stock worth $2,230,000 after purchasing an additional 3,482 shares during the period. Institutional investors own 88.87% of the company’s stock.

In other news, Director Richard A. Sandberg sold 3,000 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $16.05, for a total value of $48,150.00. Following the sale, the director now directly owns 3,000 shares of the company’s stock, valued at $48,150. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Peter Wrighton-Smith sold 10,600 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $16.68, for a total value of $176,808.00. Following the completion of the sale, the chief executive officer now directly owns 445,138 shares in the company, valued at $7,424,901.84. The disclosure for this sale can be found here. Over the last three months, insiders sold 17,700 shares of company stock worth $294,658. Insiders own 6.61% of the company’s stock.

Several brokerages recently weighed in on OXFD. Zacks Investment Research raised Oxford Immunotec Global from a “hold” rating to a “buy” rating and set a $17.00 price target on the stock in a research note on Tuesday, April 16th. BidaskClub cut Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research note on Thursday, January 31st. Finally, ValuEngine cut Oxford Immunotec Global from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, March 12th.

Shares of OXFD stock opened at $14.91 on Wednesday. The firm has a market capitalization of $404.67 million, a P/E ratio of 29.24 and a beta of 0.32. Oxford Immunotec Global PLC has a twelve month low of $11.66 and a twelve month high of $19.19. The company has a debt-to-equity ratio of 0.04, a quick ratio of 12.03 and a current ratio of 12.60.

Oxford Immunotec Global (NASDAQ:OXFD) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.06) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.14. The company had revenue of $14.79 million for the quarter, compared to analysts’ expectations of $13.74 million. Oxford Immunotec Global had a return on equity of 13.56% and a net margin of 172.27%. The firm’s revenue for the quarter was up 26.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.40) earnings per share. As a group, equities analysts anticipate that Oxford Immunotec Global PLC will post -0.28 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Oxford Immunotec Global PLC (OXFD) Position Lowered by Bank of America Corp DE” was originally published by WKRB News and is the property of of WKRB News. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.wkrb13.com/2019/05/22/oxford-immunotec-global-plc-oxfd-position-lowered-by-bank-of-america-corp-de.html.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

Featured Article: What is Blockchain?

Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).

Institutional Ownership by Quarter for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.